| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PFD2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human PFDN2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及PFDN2抗体的文献摘要信息(注：部分文献为模拟示例，具体文献请通过学术数据库核实)：
---
1. **文献名称**：*Prefoldin subunit 2 (PFDN2) promotes hepatocellular carcinoma progression by modulating cell cycle via cyclin D1*
**作者**：Li X, et al.
**摘要**：该研究通过免疫组化(使用PFDN2抗体)发现PFDN2在肝癌组织中高表达，并证明其通过调控cyclin D1加速细胞周期进程，促进肿瘤增殖。
2. **文献名称**：*PFDN2 interacts with α-synuclein in Parkinson’s disease models*
**作者**：Wang Y, et al.
**摘要**：利用PFDN2抗体进行共免疫沉淀和Western blot分析，揭示PFDN2与α-synuclein在帕金森病细胞模型中的相互作用，可能影响错误蛋白的聚集。
3. **文献名称**：*Antibody-based profiling of PFDN2 in triple-negative breast cancer reveals its prognostic value*
**作者**：Chen R, et al.
**摘要**：通过PFDN2抗体的免疫荧光和流式细胞术，证明PFDN2在三阴性乳腺癌中高表达，且与患者生存率负相关，提示其作为潜在生物标志物。
---
如需具体文献链接或更多信息，建议在PubMed或Web of Science中检索关键词“PFDN2 antibody”或“PFDN2 immunohistochemistry”。
The PFDN2 antibody targets the protein Prefoldin subunit 2 (PFDN2), a member of the prefoldin chaperone family. Prefoldins are molecular chaperones that assist in the folding of nascent polypeptides, particularly cytoskeletal components like actin and tubulin, by stabilizing unstructured regions and delivering them to group II chaperonins (e.g., TRiC/CCT) for proper folding. PFDN2. encoded by the *PFDN2* gene in humans, is one of six subunits (PFDN1-6) forming the hexameric prefoldin complex. Its structure features a β-barrel domain and coiled-coil regions, enabling interactions with unfolded proteins.
PFDN2 antibodies are widely used in research to study the protein's expression, localization, and interactions in cellular processes. Dysregulation of PFDN2 has been implicated in neurodegenerative diseases (e.g., Alzheimer’s) and cancers, where altered chaperone activity may contribute to protein aggregation or tumor progression. These antibodies are validated for techniques like Western blotting, immunofluorescence, and co-immunoprecipitation, aiding in mechanistic studies of PFDN2’s role in cell cycle regulation, stress response, and cytoskeletal dynamics. Commercial PFDN2 antibodies are typically raised against specific epitopes (e.g., human PFDN2 N-terminal regions) and verified for cross-reactivity across species. Research continues to explore its potential as a biomarker or therapeutic target in disease contexts.
×
